We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Read MoreHide Full Article
Key Takeaways
BEAM reported Q4 loss of 10 cents per share as revenues jumped to $114.1 million, beating estimates.
BEAM secured a $500M non-dilutive credit facility to support risto-cel launch in SCD.
BEAM plans risto-cel BLA by the end of 2026. Its cash runway now extends into mid-2029.
Beam Therapeutics (BEAM - Free Report) incurred a loss of 10 cents per share in the fourth quarter of 2025 (excluding gain on sale of equity method investment), narrower than the Zacks Consensus Estimate of a loss of $1.13. The company had reported a loss of $1.09 per share in the year-ago quarter.
Revenues totaled $114.1 million, beating the Zacks Consensus Estimate of $15 million. The company had recorded revenues of $30.1 million in the year-ago quarter. The top line primarily comprises license and collaboration revenues.
Over the past year, shares of Beam Therapeutics have gained 8.6% compared with the industry’s 18% rise.
Image Source: Zacks Investment Research
BEAM's Q4 Earnings in Detail
Research and development expenses were $99.3 million in the fourth quarter, down 2.1% from the year-ago quarter.
General and administrative expenses surged 12.6% year over year to $32.3 million.
As of Dec. 31, 2025, Beam Therapeutics had cash, cash equivalents and marketable securities worth $1.25 billion compared with $1.1 billion as of Sept. 30, 2025.
In a separate press release, BEAM announced that it has secured a $500 million non-dilutive senior credit facility from Sixth Street to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). The deal includes $100 million upfront payment, up to $300 million tied to clinical, regulatory and commercial milestones and an optional $100 million tranche over a seven-year term. The financing extends BEAM’s cash runway into mid-2029.
BEAM’s Full-Year 2025 Results
For 2025, Beam Therapeutics reported total revenues of $139.7 million, representing a sharp increase of 120% year over year.
BEAM's Pipeline Updates
Beam Therapeutics is developing its leading ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for the treatment of patients with SCD, an inherited blood disorder.
The company presented updated data from the BEACON study in December 2025, which continued to show evidence of risto-cel’s differentiated treatment profile in SCD patients. BEAM plans to submit a biologics licensing application (BLA) for risto-cel by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.
Dosing has been completed in the first cohort of the phase I/II study, evaluating BEAM-301 as a potential treatment for patients with GSDIa in the United States. Enrollment is now underway in the second cohort. Initial data from the study are expected in 2026.
The company is developing BEAM-302 in a phase I/II dose-escalation study for treating AATD. BEAM has aligned with the FDA on a potential accelerated approval pathway based on 12-month AAT biomarker data and plans to enroll about 50 additional patients at the selected optimal dose to support a future BLA submission.
Dosing in the ongoing phase I healthy volunteer study, evaluating BEAM-103, an anti-CD117 monoclonal antibody for treating SCD, is expected to be completed in the first half of 2026.
The company expanded its liver-targeted genetic disease franchise with BEAM-304 for the treatment of phenylketonuria (PKU) and plans to file an investigational new drug application with the FDA in 2026. PKU is a rare, inherited metabolic disorder that results in the toxic accumulation of phenylalanine, which can lead to serious neurologic and neurocognitive impairments.
Beam Therapeutics Inc. Price, Consensus and EPS Surprise
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.72 to $4.00. HRMY shares have lost 23.7% over the past year.
Harmony Biosciences’ earnings beat estimates in two of the trailing four quarters but missed in the remaining two, with the average surprise being 7.20%.
Over the past 60 days, estimates for Assertio’s 2026 loss per share have narrowed from 30 cents to 28 cents. ASRT shares have gained 1.6% over the past year.
Assertio’s earnings beat estimates in one of the trailing four quarters and missed in the remaining three, with the average negative surprise being 35.21%.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.06 to 96 cents. CSTL shares have risen 19.5% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Key Takeaways
Beam Therapeutics (BEAM - Free Report) incurred a loss of 10 cents per share in the fourth quarter of 2025 (excluding gain on sale of equity method investment), narrower than the Zacks Consensus Estimate of a loss of $1.13. The company had reported a loss of $1.09 per share in the year-ago quarter.
Revenues totaled $114.1 million, beating the Zacks Consensus Estimate of $15 million. The company had recorded revenues of $30.1 million in the year-ago quarter. The top line primarily comprises license and collaboration revenues.
Over the past year, shares of Beam Therapeutics have gained 8.6% compared with the industry’s 18% rise.
Image Source: Zacks Investment Research
BEAM's Q4 Earnings in Detail
Research and development expenses were $99.3 million in the fourth quarter, down 2.1% from the year-ago quarter.
General and administrative expenses surged 12.6% year over year to $32.3 million.
As of Dec. 31, 2025, Beam Therapeutics had cash, cash equivalents and marketable securities worth $1.25 billion compared with $1.1 billion as of Sept. 30, 2025.
In a separate press release, BEAM announced that it has secured a $500 million non-dilutive senior credit facility from Sixth Street to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). The deal includes $100 million upfront payment, up to $300 million tied to clinical, regulatory and commercial milestones and an optional $100 million tranche over a seven-year term. The financing extends BEAM’s cash runway into mid-2029.
BEAM’s Full-Year 2025 Results
For 2025, Beam Therapeutics reported total revenues of $139.7 million, representing a sharp increase of 120% year over year.
BEAM's Pipeline Updates
Beam Therapeutics is developing its leading ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for the treatment of patients with SCD, an inherited blood disorder.
The company presented updated data from the BEACON study in December 2025, which continued to show evidence of risto-cel’s differentiated treatment profile in SCD patients. BEAM plans to submit a biologics licensing application (BLA) for risto-cel by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.
Dosing has been completed in the first cohort of the phase I/II study, evaluating BEAM-301 as a potential treatment for patients with GSDIa in the United States. Enrollment is now underway in the second cohort. Initial data from the study are expected in 2026.
The company is developing BEAM-302 in a phase I/II dose-escalation study for treating AATD. BEAM has aligned with the FDA on a potential accelerated approval pathway based on 12-month AAT biomarker data and plans to enroll about 50 additional patients at the selected optimal dose to support a future BLA submission.
Dosing in the ongoing phase I healthy volunteer study, evaluating BEAM-103, an anti-CD117 monoclonal antibody for treating SCD, is expected to be completed in the first half of 2026.
The company expanded its liver-targeted genetic disease franchise with BEAM-304 for the treatment of phenylketonuria (PKU) and plans to file an investigational new drug application with the FDA in 2026. PKU is a rare, inherited metabolic disorder that results in the toxic accumulation of phenylalanine, which can lead to serious neurologic and neurocognitive impairments.
Beam Therapeutics Inc. Price, Consensus and EPS Surprise
Beam Therapeutics Inc. price-consensus-eps-surprise-chart | Beam Therapeutics Inc. Quote
BEAM’s Zacks Rank and Stocks to Consider
Beam Therapeutics currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) , Assertio Holdings (ASRT - Free Report) and Castle Biosciences (CSTL - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.72 to $4.00. HRMY shares have lost 23.7% over the past year.
Harmony Biosciences’ earnings beat estimates in two of the trailing four quarters but missed in the remaining two, with the average surprise being 7.20%.
Over the past 60 days, estimates for Assertio’s 2026 loss per share have narrowed from 30 cents to 28 cents. ASRT shares have gained 1.6% over the past year.
Assertio’s earnings beat estimates in one of the trailing four quarters and missed in the remaining three, with the average negative surprise being 35.21%.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.06 to 96 cents. CSTL shares have risen 19.5% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.